Cost-effectiveness of expanding national health insurance coverage for composite resin restorations in cancer patients in South Korea

被引:0
|
作者
Han, Areum [1 ,2 ]
Park, Eun-Gee [1 ]
Yoon, Jeong-Hwa [3 ]
Choi, Ji-Yeob [4 ,5 ]
Park, Hee-Kyung [6 ,7 ]
Hahn, Seokyung [3 ,5 ,8 ]
机构
[1] Seoul Natl Univ, Coll Med, Interdisciplinary Program Med Informat, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Integrated Major Innovat Med Sci, Seoul, South Korea
[3] Seoul Natl Univ, Med Bigdata Res Ctr, Med Res Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea
[5] Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea
[6] Seoul Natl Univ, Sch Dent, Dept Oral Med & Oral Diag, Seoul, South Korea
[7] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea
[8] Seoul Natl Univ, Coll Med, Dept Human Syst Med, 103 Daehak Ro, Seoul 03080, South Korea
基金
新加坡国家研究基金会;
关键词
Cancer patients; Dental insurance; National health insurance; Markov model; Cost-effectiveness analysis; Resin composite; Insurance coverage; XEROSTOMIC HEAD; DENTAL DISEASE; GLASS-IONOMER; ORAL-CANCER; NECK; THERAPY; MANAGEMENT; CARCINOMA; MUCOSITIS; CARIES;
D O I
10.1016/j.jdent.2024.105357
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: Cancer patients often have compromised oral health, making them vulnerable to severe dental caries and restoration failures. Due to the nature of cervical or anterior caries in cancer patients, the use of adequate restorative materials is important. However, public dental insurance coverage for composite treatments varies among countries and only glass ionomer cements (GICs) are covered in all age groups in South Korea. This study examined the cost-effectiveness of expanding national health insurance coverage to include resin composite (RC) restorations as compared with GIC in cancer patients. Methods: Data from cancer patients who received direct restoration using GIC were identified from the National Health Screening Cohort. The relative effect of RC compared to GIC was determined through a meta-analysis, which was then utilized in calculating corresponding transition probabilities within a multi-state model. A Markov-chain Monte Carlo microsimulation was performed to estimate useful life-years and total treatment costs at the tooth level. The incremental cost-effectiveness ratio (ICER) of RC versus GIC was calculated, considering scenarios with and without expanded national health insurance coverage. The robustness of the results was confirmed through various sensitivity analyses. Results: Between the two materials, RC resulted in a 0.4-year longer useful life. From a limited societal perspective, it cost $9.6 less with expanded coverage but $24.3 more without expansion, resulting in an ICER of -$25.2 and $63.9 per tooth-year, respectively. From a patient's perspective, the ICER values were -$72.7 versus $138.8 per tooth-year, respectively, translating into $200 more in savings with the expansion. Various sensitivity analyses consistently demonstrated a smaller ICER when insurance coverage was expanded. Conclusions: The expansion of national health insurance coverage to include RC restorations for cancer patients appears to be clearly cost-effective. This emphasizes the need for further policy considerations to ensure access to dental care for cancer patients. Clinical Significance: Timely management of dental caries is crucial for cancer patients, as untreated caries can escalate into severe oral conditions, negatively impacting treatment outcomes and increasing care costs. Expanding a national health insurance coverage for cancer patients in the treatment of early dental lesions is necessary to prevent advanced dental diseases.
引用
收藏
页数:8
相关论文
共 36 条
  • [21] Prevention of cervical cancer in women with ASCUS in the Brazilian Unified National Health System: cost-effectiveness of the molecular biology method for HPV detection
    Nomelini, Rosekeila Simoes
    Neto Guimaraes, Patricia Dias
    Candido, Pamela Aparecida
    Camargo Campos, Ana Claudia
    Michelin, Marcia Antoniazi
    Candido Murta, Eddie Fernando
    CADERNOS DE SAUDE PUBLICA, 2012, 28 (11): : 2043 - 2052
  • [22] Safety of High-Dose Intravenous Iron in Hemodialysis Patients: Results from the National Health Insurance Service (2019-2020) in South Korea
    Cho, Ajin
    Bae, Yoonjong
    Kim, Mina
    Kim, Do Hyoung
    Lee, Young-Ki
    Park, Hayne Cho
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (01)
  • [23] A Comparison of the Anesthetic Methods for Recurrence Rates of Bladder Cancer after Transurethral Resection of Bladder Tumors Using National Health Insurance Claims Data of South Korea
    Lee, Sang Won
    Tae, Bum Sik
    Choi, Yoon Ji
    Yoon, Sang Min
    Lee, Yoon Sook
    Kim, Jae Hwan
    Shin, Hye Won
    Park, Jae Young
    Bae, Jae Hyun
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [24] Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System
    Matter-Walstra, Klazien
    Joerger, Markus
    Kuehnel, Ursula
    Szucs, Thomas
    Pestalozzi, Bernhard
    Schwenkglenks, Matthias
    VALUE IN HEALTH, 2012, 15 (01) : 65 - 71
  • [25] A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System
    Paz-Ares, L.
    del Muro, J. G.
    Grande, E.
    Diaz, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (04) : 429 - 438
  • [26] Impact of the national health insurance coverage policy on mecapegfilgrastim utilization for chemoradiotherapy-induced neutropenia in cancer patients in China: a retrospective real-world analysis
    Fang, Wenqing
    He, Jizhong
    Wang, Ying
    Zhu, Yulei
    Qian, Xiaodan
    Su, Dan
    Gong, Jinhong
    Shang, Jingjing
    He, Yuan
    Wu, Hong
    Li, Xin
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [27] Comparative cost-effectiveness of the Heart Ware versus Heart Mate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure
    Pulikottil-Jacob, Ruth
    Suri, Gaurav
    Connock, Martin
    Kandala, Ngianga-Bakwin
    Sutcliffe, Paul
    Maheswaran, Hendramoorthy
    Banner, Nicholas R.
    Clarke, Aileen
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04) : 350 - 358
  • [28] A population-based study on the risk of prescription opioid abuse in patients with chronic opioid use and cost-effectiveness of prescription drug monitoring program using a patient simulation model in South Korea
    Kim, Siin
    Suh, Hae Sun
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 112
  • [29] Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective
    Levy, Pierre
    Lemanski, Tobiasz
    Crossan, Catriona
    Lefebvre, Anna
    Briere, Jean-Baptiste
    Degli Esposti, Luca
    Khan, Zeba M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 967 - 975
  • [30] An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
    Shafrin, Jason
    Skornicki, Michelle
    Brauer, Michelle
    Villeneuve, Julie
    Lees, Michael
    Hertel, Nadine
    Penrod, John R.
    Jansen, Jeroen
    HEALTH POLICY, 2018, 122 (06) : 607 - 613